Pharming Technologies Bv Patent-Cliff Exposure & CMS Drug Spending Portfolio

Pharming Technologies Bv (US): 1 reconciled FDA prescription therapies, $22.6M 2024 CMS Part D & Medicaid spend, and $45,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$22.6M
2024 Medicare Part D Spend$3.9M
2024 Medicaid Spend$18.7M
California HCAI SB 17 FilingsSpecialty launch notice ($45,000 intro WAC)